TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's,“ Transforming Growth Factor Beta Inhibitors Pipeline Insight 2025 ” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Transforming Growth Factor Beta Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Transforming Growth Factor Beta Inhibitors pipeline products in this space.

Download DelveInsight's comprehensive Transforming Growth Factor Beta Inhibitors Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Transforming Growth Factor Beta Inhibitors Pipeline Outlook Report

Key Takeaways from the Transforming Growth Factor Beta Inhibitors Pipeline Report

• DelveInsight's Transforming Growth Factor Beta Inhibitors pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth Factor Beta Inhibitors treatment.
• The leading Transforming Growth Factor Beta Inhibitors Companies such as Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
• Promising Transforming Growth Factor Beta Inhibitors Therapies such as Trabedersen, KER-050, STP705 , and others.

Access DelveInsight's in-depth Transforming Growth Factor Beta Inhibitors Pipeline Analysis for a closer look at promising breakthroughs @ Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies

Transforming Growth Factor Beta Inhibitors Emerging Drugs Profile

• Trabedersen: Oncotelic

Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-β2 messenger RNA. Ready for registration trials--Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.

• KER-050: Keros Therapeutics

KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.

• STP705: Sirnaomics

STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.

Get a detailed analysis of the latest innovations in the Transforming Growth Factor Beta Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ Transforming Growth Factor Beta Inhibitors Unmet Needs

Transforming Growth Factor Beta Inhibitors Companies

Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company , and others.

Transforming Growth Factor Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Transforming Growth Factor Beta Inhibitors Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming Transforming Growth Factor Beta Inhibitors Therapies and key Transforming Growth Factor Beta Inhibitors Developments @ Transforming Growth Factor Beta Inhibitors Market Drivers and Barriers, and Future Perspectives

Scope of the Transforming Growth Factor Beta Inhibitors Pipeline Report

• Coverage- Global
• Transforming Growth Factor Beta Inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
• Transforming Growth Factor Beta Inhibitors Therapies- Trabedersen, KER-050, STP705 , and others.
• Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Transforming Growth Factor Beta Inhibitors Pipeline Report-access it now! @ Transforming Growth Factor Beta Inhibitors Emerging Drugs and Major Companies

Table of Content